Seattle-based Aurion Biotech is a developer of regenerative therapies for vision loss. Aurion Biotech secured a US$ 120 million financing that was led by Deerfield Management, and included existing investors Petrichor Healthcare Capital Management, Flying L Partners, Falcon Vision, an ophthalmology-focused investment platform supported by KKR, and Visionary Ventures, a ophthalmology-focused venture fund. Alcon also…